Pharminent

PD-1 and IDO Inhibitor Combo Slated to Change Practice in Melanoma

Thomas F. Gajewski, MD, PhD, discusses how the combination of PD-1 and IDO inhibitors could change the standard of care for patients with melanoma, and highlights other emerging targets on the horizon. http://www.onclive.com/web-exclusives/pd1-and-ido-inhibitor-combo-slated-to-change-practice-in-melanoma

Filed under: Cancer, Immunotherapy